Healthcare Rotation Thesis Faces Headwinds: Regulatory Wins Offset by Valuation Pullbacks and Sector-Wide Weakness

Recent regulatory approvals for Amgen, AbbVie, and Eli Lilly support the pipeline-execution leg of the healthcare rotation thesis, but simultaneous analyst downgrades, profit-taking in high-flying biotech names, and broad sector declines suggest the defensive rotation narrative may be losing momentum.

What changed

Since the last update on August 26, the healthcare rotation thesis has received mixed signals. On the positive side, three material regulatory and clinical catalysts arrived:

Regulatory and clinical wins: Amgen and AstraZeneca's Tezspire achieved its primary endpoint in eosinophilic esophagitis, affecting an estimated 470,000 U.S. patients. Eli Lilly and Roche's Alzheimer's blood test won FDA approval. AbbVie submitted a regulatory application to the European Medicines Agency for risankizumab (SKYRIZI) as a subcutaneous induction therapy for moderately to severely active Crohn's disease.

Offsetting headwinds: Deutsche Bank downgraded Novo Nordisk (NVO) to Sell on August 27, cutting its price target by 9% to 265 Danish crowns from 290 crowns, citing persistent concerns over growth trajectory. Amgen announced it is ending its Crohn's disease research partnership. The NYSE Healthcare Index shed 1% in late-afternoon trading on August 26. Moderna sank 7% on August 24 as traders locked in profits after a 392% year-to-date surge. Eli Lilly slipped as its $1.1 trillion valuation cooled. Merck was downgraded by RBC Capital Markets following a 12.6% cancer-vaccine rally, with the analyst citing valuation concerns after the stock's surge.

Market performance: As of August 27, Amgen was up 11.9% over 30 days and Merck up 14.8%, but Novo Nordisk fell 9.6% and Eli Lilly declined 3.0% over the same period.

Why it matters

The thesis rests on two pillars: (1) defensive rotation into healthcare as AI and tech stocks sold off, and (2) pipeline execution delivering regulatory wins. The evidence now reveals a fracture in both.

On pipeline execution: The regulatory approvals for Tezspire, the Alzheimer's blood test, and SKYRIZI do support the thesis's claim that biopharma names are delivering clinical catalysts. Tezspire's positive Phase 3 results across both co-primary and key secondary endpoints represent concrete proof of concept in a disease affecting hundreds of thousands of patients. However, this evidence is partially offset by Amgen's decision to end its Crohn's partnership—a direct contradiction to the narrative of sustained pipeline momentum in inflammatory disease, one of the thesis's key therapeutic areas.

On defensive rotation: The broader picture is more troubling. The NYSE Healthcare Index declined 1% in late afternoon on August 26, and healthcare stocks fell again on August 20 and August 23. This suggests the sector is not acting as a consistent defensive haven. More critically, the analyst downgrades and profit-taking in names like Moderna (down 7% in a single session after a 392% year-to-date run) and Merck (downgraded after a 12.6% rally) indicate that the rotation narrative may have exhausted its near-term appeal. When large-cap healthcare names rally sharply on clinical wins and are immediately met with downgrades citing valuation concerns, it signals that the market is repricing these names away from the "defensive alternative" positioning that underpinned the original thesis.

Opposing sources and risks

Several sources directly contradict the thesis's core premise:

  1. Merck's AI vaccine stake (August 23): Merck took a stake in an AI vaccine company and expanded its discovery playbook, suggesting that large-cap pharma is not retreating from AI but rather integrating it into drug development. This undermines the narrative of a clean rotation away from AI into traditional biopharma.

  2. Biopharma giants gearing up for AI drug-making (August 21): Multiple sources note that biopharma companies are actively adopting AI for drug discovery and development, blurring the line between "AI stocks" and "healthcare stocks." If the largest pharma names are themselves becoming AI-enabled, the thesis's assumption of a binary choice between AI and healthcare rotation becomes less valid.

  3. Sector-wide declines (August 26, August 20, August 23): The NYSE Healthcare Index fell 1%, 0.7%, and 0.9% on three separate trading days in late August, contradicting the narrative that healthcare is a safe haven. A true defensive rotation would show healthcare holding up better during broader market stress.

What to watch

Carry-forward items:

  • Continued regulatory approval progress for Merck's RSV vaccine and other pipeline candidates.
  • Resolution of legal disputes concerning retatrutide and illicit weight-loss drug markets.
  • Further clinical trial results for Novo Nordisk's pipeline candidates, particularly given the Deutsche Bank downgrade.
  • Analyst sentiment and price target revisions for large-cap healthcare names, especially AbbVie and Eli Lilly, as valuations stabilize or compress further.
  • Ongoing market share dynamics between Eli Lilly and Novo Nordisk in the GLP-1 space, with particular attention to whether Novo's growth concerns are justified.

New items:

  • Whether healthcare sector weakness persists or reverses; if the NYSE Healthcare Index continues to decline, the defensive rotation thesis will be invalidated.
  • Analyst downgrades and valuation resets for Merck, Moderna, and other high-flyers; a cascade of downgrades would signal the rotation trade is exhausted.
  • Evidence of whether Amgen's Crohn's partnership exit signals a broader retreat from inflammatory disease or is an isolated portfolio decision.
  • Tracking whether large-cap pharma's AI investments (e.g., Merck's vaccine stake) accelerate, which would blur the AI-versus-healthcare dichotomy further.

Related Arbora context

This thesis sits at the intersection of several related concepts:

  • GLP-1 and obesity drug coverage expansion (concept-glp1-obesity-drug-coverage): The rotation into healthcare is partly driven by the GLP-1 tailwind, but recent profit-taking in Novo Nordisk and Eli Lilly suggests that GLP-1 momentum may be moderating.
  • Healthcare managed care and aging demographics (concept-healthcare-managed-care-aging-demographics): This thesis offers a more structural, long-term defensive case for healthcare, distinct from the short-term rotation narrative. If the rotation thesis falters, the managed-care thesis may provide a more durable foundation.
  • Pfizer and large-cap pharma value recovery (concept-pfizer-largecap-pharma-value-recovery): The valuation compression now evident in Eli Lilly and Merck may create value opportunities in other large-cap pharma names, but it also suggests the sector is repricing downward, not upward.
  • AbbVie large-cap pharma M&A pipeline build (concept-abbvie-largecap-pharma-ma-pipeline-build): AbbVie's regulatory submission for SKYRIZI supports the M&A thesis's claim that large-cap pharma is actively building pipelines, but sector-wide weakness may constrain M&A multiples going forward.

Opposing sources and risks (expanded)

A second risk: if biopharma companies continue to integrate AI into their drug-discovery pipelines (as Merck's vaccine stake suggests), the thesis's core assumption—that investors face a binary choice between AI and healthcare—becomes invalid. In that scenario, healthcare names would not be a hedge against AI but rather a different expression of the same AI trend.

Sources

This article is research notes, not financial advice.